AbbVie and Tentarix Biotherapeutics Join Forces for the Development of Biologics for Oncology and Immunology
Shots:
- AbbVie and Tentarix have entered into a multi-year collaboration to discover and develop multifunctional biologics for oncological & immunological diseases by combining Tentarix's Tentacles platform with AbbVie's expertise in oncology & immunology
- Under the collaboration, Tentarix is entitled to receive a total of $64M as an upfront option payment for the two programs while AbbVie gains an exclusive option for their acquisition & nomination for an additional undisclosed payment for each program
- Tentacles are conditionally-active, multi-functional, Ab-based biologics for immune cell activation to regulate disease pathways, minimizing safety concerns linked with non-specific targeting of other immune cells
Ref: AbbVie | Image: AbbVie
Related News:- Gilead Entered into a Multi-Year Collaboration Agreement with Tentarix to Discover and Develop Novel Therapies for Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
